Shots:

• Amgen- UCB- and Takeda reported that the first patient has been enrolled in the COMMUNITY trial. The study will test whether Amgen’s Otezla- Takeda’s lanadelumab- and UCB’s zilucoplan can reduce the severity of COVID-19 in hospitalized patients by moderating the immune system’s response to the disease
• The focus of the trial is to identify an effective treatment for hospitalized COVID-19 patients- who are Grade 2 to Grade 5 on a clinical severity status 8-point ordinal scale. Trial sites are being established in hospitals across the globe to support enrollment in communities
• This is the first time that the global pharmaceutical has come together to launch an adaptive clinical trial

 ­ Ref: Takeda | Image: Stat